News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Jul 09, 2020, 18:32 ET FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
Jul 07, 2020, 08:00 ET AbbVie to Host Second-Quarter 2020 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its second-quarter 2020 financial results on Friday, July 31, 2020, before the market opens. AbbVie will host a...
Jul 01, 2020, 15:17 ET AbbVie Apresenta Dados de Estudo que Indicam Superioridade de SKYRIZI® (risanquizumabe) na Melhora das Lesões de Pele em Pacientes com Psoríase em Placas, em Comparação com Secuquinumabe, em 52 Semanas de Tratamento
A AbbVie (NYSE: ABBV), companhia biofarmacêutica global baseada em pesquisa, anunciou novos dados de estudo de fase 3b, que indicam superioridade de...
Jun 26, 2020, 01:15 ET Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of...
Jun 23, 2020, 07:30 ET IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) will review...
Jun 22, 2020, 08:00 ET FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental...
Jun 18, 2020, 08:45 ET RINVOQ™ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced upadacitinib (15 mg and 30 mg, once daily) monotherapy met...
Jun 17, 2020, 10:32 ET AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. The cash dividend is payable August...
Jun 15, 2020, 08:15 ET FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region
Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® VOLUMA™ XC for the augmentation of the chin region ...
Jun 15, 2020, 08:00 ET AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has 27 studies accepted to the virtual 2020 Annual...
Jun 13, 2020, 02:30 ET VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the positive results from the VIALE-A (M15-656) trial, which...
Jun 12, 2020, 16:45 ET AbbVie Recommends Shareholders Reject TRC Capital's "Mini-Tender" Offer
AbbVie (NYSE:ABBV) has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited "mini-tender" offer, dated...
Jun 12, 2020, 15:02 ET AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior ...
Jun 10, 2020, 08:15 ET Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from a Phase 2a study of ABBV-3373, an...
Jun 10, 2020, 06:00 ET AbbVie and Genmab Announce Broad Oncology Collaboration
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly...
Jun 06, 2020, 08:30 ET AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new Phase 3 data from the SELECT-CHOICE clinical trial,...
Jun 05, 2020, 06:00 ET AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a...
Jun 04, 2020, 08:30 ET New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib...
Jun 03, 2020, 08:00 ET AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the virtual Goldman Sachs 41st Annual Global Healthcare...
Jun 01, 2020, 11:40 ET AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has submitted applications for a new indication to...
Jun 01, 2020, 08:30 ET Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is initiating a new digital campaign to improve device tracking and further identify and reach...
Jun 01, 2020, 01:00 ET AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today...
May 29, 2020, 16:14 ET FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA)...
May 27, 2020, 08:30 ET AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new safety and efficacy results for...
May 21, 2020, 10:46 ET AbbVie Announces 26 Nonprofits Selected for the COVID-19 Community Resilience Fund
AbbVie, a research-based global biopharmaceutical company, today announced donations to 26 nonprofit organizations totaling $5 million to support...
